Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABG Acquisition Corp. IABGI · Entity 115963 | Director · Chief Financial Officer | December 14, 2022 | December 20, 2022 |
| KESTRA MEDICAL TECHNOLOGIES, LTD.KMTS · Entity 4686 | Director | September 08, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABG Acquisition Corp. I
Report date December 14, 2022 · Filed December 20, 2022
This filing explicitly reported no securities owned.
KESTRA MEDICAL TECHNOLOGIES, LTD.
Report date September 08, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 12,585 |
Ending reported balance
After 2026-09-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-08 · Sale · Disposed 2,932 · Balance 5,368 F1: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units. F2: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.3500. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. Row 2 · 2026-09-09 · Grant · Acquired 7,217 · Balance 12,585 F3: The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
F2: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.3500. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
F3: The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 11, 2026 00:26 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | GrantCommon Shares | 7,217 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-388298 · ownership.xml · nonDerivative · entry 2 Reilly Kevin C · CIK 0001958127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,585 F3 · shares: The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date. F3 · price: The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date. Read SEC document |
| September 08, 2026 Filed Sep 11, 2026 00:26 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | SaleCommon Shares | 2,932 | $25.13 | $73,677.35 |
DisclosureSEC source: 0001193125-26-388298 · ownership.xml · nonDerivative · entry 1 Reilly Kevin C · CIK 0001958127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,368 F1 · kind: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units. F2 · price: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.3500. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. Read SEC document |
| March 11, 2026 Filed Mar 12, 2026 20:16 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | GrantCommon Shares | 8,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-104188 · ownership.xml · nonDerivative · entry 1 Reilly Kevin C · CIK 0001958127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,300 F1 · price: The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.